Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $1.31 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
• Arca Biopharma (ABIO) Reports Q1 Loss of $0.14